Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II studyAnna Maria Di Giacomo, Michele Maio, Alessandro Testori et al.|Annals of Oncology|2014Cited by 139
A randomized, phase III study of fotemustine versus the combination of fotemustine and ipilimumab or the combination of ipilimumab and nivolumab in patients with metastatic melanoma with brain metastasis: the NIBIT-M2 trial.Anna Maria Di Giacomo, Michele Maio, Diego Annesi et al.|Journal of Clinical Oncology|2015Cited by 8
Phase II multicenter trial of ipilimumab combined with fotemustine in patients with metastatic melanoma: The Italian Network for Tumor Biotherapy (NIBIT)-M1 trial.Anna Maria Di Giacomo, Michele Maio, Paolo A. Ascierto et al.|Journal of Clinical Oncology|2012Cited by 7